U.S. market Closed. Opens in 1 hour 38 minutes

SNY | Sanofi Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 47.61 - 48.03
52 Week Range 45.22 - 58.97
Beta 0.58
Implied Volatility 27.02%
IV Rank 52.96%
Day's Volume 1,253,580
Average Volume 1,873,210
Shares Outstanding 2,507,180,000
Market Cap 119,793,060,400
Sector Healthcare
Industry Drug Manufacturers - General
IPO Date 2002-07-01
Valuation
Profitability
Growth
Health
P/E Ratio 25.15
Forward P/E Ratio 11.86
EPS 1.90
1YR Price Target 64.00
Dividend Yield 4.24%
Dividend Per Share 2.03
Dividend ExDate 2023-05-30
Dividend PayDate 2023-06-23
Employees 86,088
Country France
Website SNY
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
SNY's peers: AMRN, AZN, BIIB, GRFS, GSK, NVS, OGN, RHHBY, MRK, BMY, GILD, BAYRY, AMGN, ABBV, JNJ, SCLX
*Chart delayed
Analyzing fundamentals for SNY we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is very poor, Growth is very good and Health is passable. For more detailed analysis please see SNY Fundamentals page.

Watching at SNY technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SNY Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙